At the end of the latest market close, Translate Bio Inc. (TBIO) was valued at $14.74. In that particular session, Stock kicked-off at the price of $14.74 while reaching the peak value of $14.84 and lowest value recorded on the day was $14.1201. The stock current value is $15.63.
Recently in News on October 7, 2020, Translate Bio Highlights mRNA Platform Potential for the Treatment of Cystic Fibrosis (CF) at the 34th Annual North American Cystic Fibrosis Conference. — Lead candidate MRT5005 leverages Translate Bio’s proprietary LNP and mRNA platform and is the only clinical-stage mRNA therapeutic in development for the treatment of CF –. You can read further details here
Get Ready for my next COVID-19 stock idea. I have been very fortunate in discovering biotech, therapeutic and diagnostic companies within the COVID-19 space, before wall street catches on. Our goal for our members is to get our Alert’s first before the crowd.
Translate Bio Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $28.09 on 06/24/20, with the lowest value was $6.80 for the same time period, recorded on 03/09/20.
Translate Bio Inc. (TBIO) full year performance was 64.51%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Translate Bio Inc. shares are logging -44.38% during the 52-week period from high price, and 129.78% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $6.80 and $28.09.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 769887 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Translate Bio Inc. (TBIO) recorded performance in the market was 81.08%, having the revenues showcasing -16.01% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 1.07B, as it employees total of 93 workers.
The Analysts eye on Translate Bio Inc. (TBIO)
During the last month, 0 analysts gave the Translate Bio Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 16.09, with a change in the price was noted -3.78. In a similar fashion, Translate Bio Inc. posted a movement of -19.67% for the period of last 100 days, recording 1,638,537 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for TBIO is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Technical rundown of Translate Bio Inc. (TBIO)
Raw Stochastic average of Translate Bio Inc. in the period of last 50 days is set at 85.27%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 87.38%. In the last 20 days, the company’s Stochastic %K was 79.00% and its Stochastic %D was recorded 74.68%.
Considering, the past performance of Translate Bio Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 81.08%. Additionally, trading for the stock in the period of the last six months notably improved by 40.78%, alongside a boost of 64.51% for the period of the last 12 months. The shares increased approximately by 13.38% in the 7-day charts and went up by 12.86% in the period of the last 30 days. Common stock shares were lifted by -16.01% during last recorded quarter.